|
|
| (99 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | __NOTOC__ | | __NOTOC__ |
| | *'''[[Further reading]]''' | | *'''[[Further reading]]''' |
| | + | |
| | | | |
| | *'''[[Unproven ideas]]''' | | *'''[[Unproven ideas]]''' |
| − | {{tp|p=32311318|t=ä. SARS-CoV-2 and ''viral sepsis'': observations and hypotheses |pdf=|usr=}}
| |
| − | {{tp|p=32325026|t=2020. Endothelial cell infection and endotheliitis in COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Reviews on covid19 disease]]''' | | *'''[[Reviews on covid19 disease]]''' |
| − | {{tp|p=32363726|t=2020. The Novel Coronavirus - Latest Findings |pdf=|usr=}}
| + | *'''[[Clinical guidelines and advice]]''' |
| − | {{tp|p=32144890|t=2020. The Novel Coronavirus ? A Snapshot of Current Knowledge |pdf=|usr=}}
| + | |
| − | {{tp|p=32032682|t=ä. Pathogenicity and transmissibility of 2019-nCoV?A quick overview and comparison with other emerging viruses |pdf=|usr=}}
| + | |
| − | {{tp|p=32017984|t=2020. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32226946|t=ä. COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don?t |pdf=|usr=}}
| + | |
| − | {{tp|p=32169119|t=2020. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak ? an update on the status |pdf=|usr=}}
| + | |
| − | {{tp|p=32297723|t=2020. COVID-2019: update on epidemiology, disease spread and management |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| − | *'''[[Clinical guidelines and advice]]''' | + | |
| − | {{tp|p=C7155395|t=ä. German recommendations for critically ill patients with COVID?19 |pdf=|usr=}}
| + | *'''[[Respiration mgmt]]''' |
| − | {{tp|p=32166350|t=ä. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32029004|t=2020. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) |pdf=|usr=}}
| + | *'''[[Diagnosis (Laboratory)]]''' |
| − | {{ttp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
| + | |
| | + | |
| | + | *'''[[Diagnosis (Lung CT, Sonography)]]''' |
| | + | |
| | + | *'''[[Diagnosis (other modalities)]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Structure of covid19]]''' | | *'''[[Structure of covid19]]''' |
| − | {{tp|p=32350227|t=2020. Characteristics of SARS-CoV-2 isolated from asymptomatic carrier in Tokyo |pdf=|usr=}}
| |
| − | {{tp|p=32007145|t=2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding |pdf=|usr=}}
| |
| − | {{tp|p=32342926|t=2020. Properties of Coronavirus and SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32194253|t=ä. Molecular basis of COVID-19 relationships in different species: a one health perspective |pdf=|usr=}}
| |
| − | {{tp|p=32302675|t=ä. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses |pdf=|usr=}}
| |
| − | {{tp|p=32165386|t=2020. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal |pdf=|usr=}}
| |
| − | {{ttp|p=32289821|t=ä. Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Target binding and uptake]]''' | | *'''[[Target binding and uptake]]''' |
| − | {{tp|p=32199943|t=ä. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{ttp|p=32362314|t=ä. A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells |pdf=|usr=}}
| |
| − |
| |
| | *'''[[Cytopathic effects]]''' | | *'''[[Cytopathic effects]]''' |
| − |
| |
| | *'''[[Secretion and shedding]]''' | | *'''[[Secretion and shedding]]''' |
| − | {{tp|p=32304647|t=2020. SARS-CoV-2 shedding and infectivity |pdf=|usr=}}
| |
| − | {{tp|p=32304646|t=ä. SARS-CoV-2 shedding and infectivity ? Authors reply |pdf=|usr=}}
| |
| | | | |
| | | | |
| Zeile 51: |
Zeile 34: |
| | | | |
| | *'''[[Immunology]]''' | | *'''[[Immunology]]''' |
| − | {{tp|p=32259560|t=ä. Interleukin-6 as a potential biomarker of COVID-19 progression |pdf=|usr=}}
| |
| − | {{ttp|p=32092539|t=2020. Is COVID-19 receiving ADE from other coronaviruses?|pdf=|usr=}}
| |
| − | {{tp|p=32268188|t=ä. It is too soon to attribute ADE to COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32361001|t=ä. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes |pdf=|usr=}}
| |
| − | {{ttp|p=32305501|t=ä. The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement |pdf=|usr=}}
| |
| − | {{tp|p=32248387|t=ä. Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' | | *'''[[Cytokine storm, hemophagocytic lymphohistiocytosis, macrophage activation syndrome]]''' |
| − | {{tp|p=32353251|t=ä. COVID-19 cytokine storm: the interplay between inflammation and coagulation |pdf=|usr=}}
| |
| − | {{tp|p=32339596|t=ä. Predictive factors of poor outcomes in the COVID-19 epidemic: Consider the inflammatory response |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Pathobiology]]''' |
| | | | |
| | | | |
| | + | *'''[[Disease Models]]''' |
| | | | |
| − | *'''[[Early symptoms]]'''
| |
| | | | |
| − | *'''[[Systemic disease, any manifestations]]''' | + | *'''[[Similar diseases and pathomechanisms]]''' |
| | | | |
| − | *'''[[Co-Infection]]'''
| |
| − | {{tp|p=32307254|t=ä. Invasive fungal diseases during COVID-19: We should be prepared |pdf=|usr=}}
| |
| − | {{tp|p=32297939|t=ä. SARS-CoV-2 and Legionella Co-infection in a Person Returning from a Nile Cruise |pdf=|usr=}}
| |
| − | {{tp|p=32293646|t=ä. Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[ARDS]]'''
| |
| | | | |
| − | *'''[[Pulmonary embolism, coagulation]]''' | + | *'''[[Early symptoms]]''' |
| − | {{tp|p=32330428|t=ä. Hospital-based use of thromboprophylaxis in patients with COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[Systemic disease, any manifestations]]''' |
| | | | |
| | + | *'''[[Co-Infection]]''' |
| | | | |
| − | *'''[[Hematology]]'''
| |
| | | | |
| − | *'''[[Microvascular]]''' | + | *'''[[Pulmonary embolism, coagulation]]''' |
| | | | |
| − | *'''[[Heart]]'''
| |
| − | {{tp|p=32334650|t=ä. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes |pdf=|usr=}}
| |
| − | {{tp|p=32360126|t=2020. Myocardial injury and COVID-19: Possible mechanisms |pdf=|usr=}}
| |
| | | | |
| − | {{tp|p=32319272|t=2020. COVID-19 and cardiovascular disorder |pdf=|usr=}}
| |
| − | {{tp|p=32340429|t=2020. The role of natriuretic peptide estimation in severe COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Neurology, ophthalmology, orl]]'''
| |
| − | {{tp|p=32305563|t=ä. Features of anosmia in COVID-19 |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Dermatology]]''' | + | *'''[[Hematology]]''' |
| | | | |
| | | | |
| − | *'''[[Gastroenterology, hepatology]]'''
| |
| − | {{tp|p=32336473|t=ä. COVID-19 y aparato digestivo |pdf=|usr=}}
| |
| − | {{tp|p=32240876|t=2020. Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms |pdf=|usr=}}
| |
| − | {{tp|p=32342369|t=2020. Wie das Coronavirus den Magen-Darm-Trakt angreift: Seminar / Gastromodul |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Kidney, urology]]''' | + | *'''[[Heart]]''' |
| − | ----
| + | |
| | | | |
| | | | |
| − | *'''[[Pathobiology]]'''
| |
| − | {{tp|p=32243911|t=ä. C-reactive protein levels in the early stage of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32291399|t=ä. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies |pdf=|usr=}}
| |
| | | | |
| − | *'''[[Disease Models]]''' | + | *'''[[Neurology, ophthalmology, orl]]''' |
| | | | |
| − | *'''[[Similar diseases and pathomechanisms]]'''
| |
| − | {{tp|p=32370951|t=ä. Missed or Delayed Diagnosis of Kawasaki Disease During the 2019 Novel Coronavirus Disease (COVID-19) Pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32341622|t=2020. SARS-CoV-2: Camazotz s Curse |pdf=|usr=}}
| |
| − | {{tp|p=32246819|t=2020. Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Dermatology]]''' |
| | | | |
| | | | |
| − | ----
| |
| | | | |
| | + | *'''[[Gastroenterology, hepatology]]''' |
| | | | |
| − | *'''[[Diagnosis (Laboratory)]]''' | + | *'''[[Kidney, urology]]''' |
| − | {{tp|p=32333644|t=2020. RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2 |pdf=|usr=}}
| + | |
| − | {{tp|p=32183357|t=2020. 2019 Novel Coronavirus Disease (COVID-19): Paving the Road for Rapid Detection and Point-of-Care Diagnostics |pdf=|usr=}}
| + | |
| − | {{tp|p=32106462|t=2020. Disposable DNA Amplification Chips with Integrated Low-Cost Heaters ? |pdf=|usr=}}
| + | |
| | | | |
| | + | *'''[[The morbid survivor]]''' |
| | | | |
| | + | *'''[[Risk and special populations]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (Lung CT, Sonography)]]'''
| |
| − | {{tp|p=32367213|t=ä. CT-Verlauf einer Coronavirus(2019-nCoV)-Pneumonie |pdf=|usr=}}
| |
| − | {{tp|p=32358406|t=2020. COVID-19 with cystic features on computed tomography: A case report |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Case reports]]''' |
| | | | |
| | | | |
| − | *'''[[Diagnosis (other modalities)]]'''
| |
| − | {{tp|p=32344326|t=2020. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Respiration mgmt]]'''
| |
| − | {{tp|p=32336080|t=2020. Extracorporeal membrane oxygenation for critically ill patients with coronavirus-associated disease 2019: an updated perspective of the European experience |pdf=|usr=}}
| |
| − | {{tp|p=32236089|t=2020. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR) |pdf=|usr=}}
| |
| − | {{tp|p=32268719|t=2020. Intubation and mechanical ventilation of patients with COVID-19: what should we tell them?|pdf=|usr=}}
| |
| | | | |
| | | | |
| | | | |
| − | *'''[[Risk and special populations]]''' | + | *'''[[Case series]]''' |
| − | {{tp|p=32333196|t=2020. Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak |pdf=|usr=}}
| + | |
| − | {{tp|p=32271125|t=2020. Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management |pdf=|usr=}}
| + | |
| − | {{tp|p=32220612|t=2020. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China |pdf=|usr=}}
| + | |
| − | {{tp|p=32220611|t=2020. Commentary: COVID-19 in patients with diabetes |pdf=|usr=}}
| + | |
| − | {{tp|p=32275971|t=ä. COVID-19 in patients with diabetes: risk factors that increase morbidity |pdf=|usr=}}
| + | |
| − | {{tp|p=32360211|t=ä. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32360397|t=ä. Mechanisms of increased morbidity and mortality of SARS-CoV-2 infection in individuals with diabetes: what this means for an effective management strategy |pdf=|usr=}}
| + | |
| − | {{tp|p=32353356|t=ä. Obesity: the ?Achilles heel? for COVID-19?|pdf=|usr=}}
| + | |
| − | {{tp|p=32333939|t=2020. Importance of metabolic health in the era of COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32333938|t=2020. Obesity hypoventilation syndrome and severe COVID-19 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320741|t=2020. Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease |pdf=|usr=}}
| + | |
| − | {{tp|p=32320740|t=ä. Low-density lipoprotein is a potential predictor of poor prognosis in patients with coronavirus disease 2019 |pdf=|usr=}}
| + | |
| − | {{tp|p=32320742|t=ä. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next? |pdf=|usr=}}
| + | |
| − | {{tp|p=32271728|t=2020. Coronavirus Disease 2019 in Children - United States, February 12?April 2, 2020 |pdf=|usr=}}
| + | |
| − | {{tp|p=32345328|t=2020. Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection |pdf=|usr=}}
| + | |
| | | | |
| − |
| |
| − |
| |
| − | *'''[[The morbid survivor]]'''
| |
| − | {{tp|p=32219356|t=ä. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32369030|t=2020. Considerations for Postacute Rehabilitation for Survivors of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32333842|t=2020. The key role of palliative care in response to the COVID-19 tsunami of suffering |pdf=|usr=}}
| |
| − | {{tp|p=32197096|t=ä. COVID-19 in pregnant women ? Authors reply |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − |
| |
| − | *'''[[Case reports]]'''
| |
| − | {{tp|p=32224310|t=ä. Clinical and virological data of the first cases of COVID-19 in Europe: a case series |pdf=|usr=}}
| |
| − | {{tp|p=32164830|t=2020. COVID-19 with spontaneous pneumomediastinum |pdf=|usr=}}
| |
| − | {{tp|p=32229159|t=ä. SARS-CoV-2 infection presenting with hematochezia |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | *'''[[Case series]]'''
| |
| − | {{tp|p=32220650|t=ä. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study |pdf=|usr=}}
| |
| − | {{tp|p=32087116|t=2020. Asymptomatic cases in a family cluster with SARS-CoV-2 infection |pdf=|usr=}}
| |
| − | {{tp|p=32105632|t=ä. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study |pdf=|usr=}}
| |
| − | {{tp|p=32379729|t=2020. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32214079|t=2020. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32290644|t=2020. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India |pdf=|usr=}}
| |
| | | | |
| | *'''[[Registries]]''' | | *'''[[Registries]]''' |
| − | {{tp|p=32305438|t=ä. The AAD COVID-19 Registry: Crowdsourcing Dermatology in the Age of COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32309814|t=ä. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries |pdf=|usr=}}
| |
| − |
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Trials]]''' | | *'''[[Trials]]''' |
| − | {{tp|p=32290293|t=2020. A Review of SARS-CoV-2 and the Ongoing Clinical Trials |pdf=|usr=}}
| |
| − | {{tp|p=32363333|t=ä. A real-time dashboard of clinical trials for COVID-19 |pdf=|usr=}}
| |
| | | | |
| | *'''[[Candidate Compounds Covid19]]''' | | *'''[[Candidate Compounds Covid19]]''' |
| − | {{tp|p=C7158785|t=ä. Convalescent plasma: A possible treatment of COVID-19 in India |pdf=|usr=}}
| |
| − | {{tp|p=32217166|t=2020. Chloroquine and COVID-19, where do we stand?? |pdf=|usr=}}
| |
| − | {{tp|p=32240719|t=ä. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection |pdf=|usr=}}
| |
| − | {{tp|p=32353355|t=ä. Testosterone, a key hormone in the context of COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344177|t=2020. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect |pdf=|usr=}}
| |
| − | {{tp|p=32305500|t=ä. Chloroquine paradox may cause more damage than help fight COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32370766|t=2020. Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines |pdf=|usr=}}
| |
| − | {{tp|p=32307014|t=2020. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32255312|t=2020. A possible probiotic (S salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2 |pdf=|usr=}}
| |
| − | {{tp|p=32365556|t=2020. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-gamma as Candidates for Cytokine Storm Modulation in COVID-19 Disease |pdf=|usr=}}
| |
| − | {{tp|p=32316270|t=2020. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help |pdf=|usr=}}
| |
| − | {{tp|p=32231349|t=2020. Chloroquine in COVID-19: the evidence |pdf=|usr=}}
| |
| − | {{tp|p=32231348|t=2020. Emerging prophylaxis strategies against COVID-19 |pdf=|usr=}}
| |
| | | | |
| | | | |
| | + | *'''[[Other routes of infection]]''' |
| | | | |
| − | ----
| |
| | | | |
| − | *'''[[Remission, recurrence and persistence]]''' | + | *'''[[Biophysics of aerosols]]''' |
| − | {{tp|p=32303482|t=ä. Re-emergence of SARS-CoV2 in a discharged COVID-19 case |pdf=|usr=}}
| + | |
| − | {{tp|p=32299784|t=ä. How do we decide to de-isolate COVID-19 patients?|pdf=|usr=}}
| + | |
| − | {{tp|p=32105304|t=2020. Positive RT-PCR Test Results in Patients Recovered From COVID-19 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| − | *'''[[Other routes of infection]]'''
| |
| − | {{tp|p=32276848|t=ä. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019 |pdf=|usr=}}
| |
| − | {{tp|p=32224116|t=ä. Do children need a longer time to shed SARS-CoV-2 in stool than adults?|pdf=|usr=}}
| |
| − | {{tp|p=32035510|t=2020. 2019-nCoV transmission through the ocular surface must not be ignored |pdf=|usr=}}
| |
| − | {{tp|p=32199469|t=2020. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Passive protective equipment]]''' |
| | | | |
| − | *'''[[Biophysics of aerosols]]'''
| |
| − | {{tp|p=32340347|t=2020. Airborne Transmission Route of COVID-19: Why 2 Meters/6 Feet of Inter-Personal Distance Could Not Be Enough |pdf=|usr=}}
| |
| − | {{tp|p=32360356|t=ä. Putting some context to the aerosolization debate around SARS-CoV-2 |pdf=|usr=}}
| |
| − |
| |
| − |
| |
| − | *'''[[Passive protective equipment]]'''
| |
| − | {{tp|p=32129805|t=2020. Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient |pdf=|usr=}}
| |
| − | {{tp|p=32203710|t=2020. Rational use of face masks in the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32344688|t=2020. 3-D Printed Protective Equipment during COVID-19 Pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Running your hospital]]''' | | *'''[[Running your hospital]]''' |
| − | {{tp|p=32322988|t=ä. Umgang mit COVID-19 in der Notaufnahme: Erfahrungsbericht der interdisziplinären Notaufnahme des Universitätsklinikums Münster |pdf=|usr=}}
| |
| − | {{tp|p=32329322|t=2020. In considerations of robotic colorectal surgery within a COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32327626|t=2020. Management of inflammatory bowel disease during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32225135|t=2020. Pathways for urology patients during the COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32202401|t=2020. Urology practice during COVID-19 pandemic |pdf=|usr=}}
| |
| − | {{tp|p=32253371|t=2020. Impact of the COVID-19 pandemic on urology residency training in Italy |pdf=|usr=}}
| |
| − | {{tp|p=32368875|t=2020. Guide for Nuclear Medicine Applications During the COVID-19 Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32210421|t=2020. COVID-19 in intensive care Some necessary steps for health care workers |pdf=|usr=}}
| |
| − | {{tp|p=32297490|t=2020. COVID-19 pandemic: what consequences for cardiac rehabilitation?|pdf=|usr=}}
| |
| − | ----
| |
| | | | |
| | | | |
| | *'''[[Mental aspects of health professionals]]''' | | *'''[[Mental aspects of health professionals]]''' |
| − | {{tp|p=32035030|t=2020. The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus |pdf=|usr=}}
| |
| − | {{tp|p=32085839|t=2020. Mental health care for medical staff in China during the COVID-19 outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32291383|t=2020. Psychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 2020 During the Outbreak of Coronavirus Disease 2019 (COVID-19) in Hubei, China |pdf=|usr=}}
| |
| | | | |
| | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' | | *'''[[Socio-psychiatric aspects of the status hygienicus]]''' |
| − | {{tp|p=32294078|t=2020. Comparison of the Indicators of Psychological Stress in the Population of Hubei Province and Non-Endemic Provinces in China During Two Weeks During the Coronavirus Disease 2019 (COVID-19) Outbreak in February 2020 |pdf=|usr=}}
| + | |
| | | | |
| | | | |
| | | | |
| | *'''[[Avoiding clinical medicine in other diseases]]''' | | *'''[[Avoiding clinical medicine in other diseases]]''' |
| − | {{tp|p=32283124|t=ä. Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States during COVID-19 Pandemic |pdf=|usr=}}
| |
| | | | |
| | | | |
| − | *'''[[Occupational medicine, workplace security and status hygienicus]]'''
| |
| − | {{tp|p=32305069|t=ä. Protecting workers aged 60?69 years from COVID-19 |pdf=|usr=}}
| |
| − | {{tp|p=32219471|t=ä. Mutterschutz ? auch im Zeitalter der Coronakrise |pdf=|usr=}}
| |
| | | | |
| | + | *'''[[Occupational medicine, workplace security and status hygienicus]]''' |
| | | | |
| | | | |
| | *'''[[Economic aspects of the status hygienicus]]''' | | *'''[[Economic aspects of the status hygienicus]]''' |
| − |
| |
| − |
| |
| | | | |
| | | | |
| Zeile 294: |
Zeile 145: |
| | | | |
| | *'''[[Host, vector, one health, atmospheric aspects]]''' | | *'''[[Host, vector, one health, atmospheric aspects]]''' |
| − | {{tp|p=32236594|t=2020. Possibility of transmission through dogs being a contributing factor to the extreme Covid-19 outbreak in North Italy |pdf=|usr=}}
| |
| − |
| |
| | | | |
| | *'''[[Origin of Covid19]]''' | | *'''[[Origin of Covid19]]''' |
| | + | |
| | *'''[[Epidemiology]]''' | | *'''[[Epidemiology]]''' |
| − | {{tp|p=32282789|t=2020. Public Health Interventions to Mitigate Early Spread of SARS-CoV-2 in Poland |pdf=|usr=}}
| |
| − | {{tp|p=32244041|t=2020. Shell disorder analysis predicts greater resilience of the SARS-CoV-2 (COVID-19) outside the body and in body fluids |pdf=|usr=}}
| |
| − | {{tp|p=32088333|t=2020. Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases |pdf=|usr=}}
| |
| − | {{tp|p=32087334|t=2020. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future |pdf=|usr=}}
| |
| − | {{tp|p=32278074|t=ä. Emergency response to the outbreak of COVID-19: the Korean case |pdf=|usr=}}
| |
| − | {{tp|p=32379733|t=2020. Public Health Response to the Initiation and Spread of Pandemic COVID-19 in the United States, February 24-April 21, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32379731|t=2020. COVID-19 Among Workers in Meat and Poultry Processing Facilities - 19 States, April 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32352957|t=2020. Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters - Four U S Cities, March 27-April 15, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32134909|t=2020. Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 - United States, January-February 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32324720|t=2020. Cleaning and Disinfectant Chemical Exposures and Temporal Associations with COVID-19 ? National Poison Data System, United States, January 1, 2020?March 31, 2020 |pdf=|usr=}}
| |
| − | {{tp|p=32298247|t=2020. Characteristics of Health Care Personnel with COVID-19 - United States, February 12-April 9, 2020 |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | |
| | + | |
| | + | |
| | + | *'''[[Remission, recurrence and persistence]]''' |
| | | | |
| | | | |
| Zeile 316: |
Zeile 160: |
| | *'''[[Failure of executive measures]]''' | | *'''[[Failure of executive measures]]''' |
| | ---- | | ---- |
| | + | *'''[[Failure of politics and public health guidance]]''' |
| | | | |
| | | | |
| | *'''[[Political abuse of Covid19]]''' | | *'''[[Political abuse of Covid19]]''' |
| − |
| |
| | | | |
| | | | |
| Zeile 325: |
Zeile 169: |
| | *'''[[Lost people]]''' | | *'''[[Lost people]]''' |
| | | | |
| − | {{tp|p=32334040|t=ä. The fate of house cats during the COVID-19 pandemic |pdf=|usr=}}
| |
| | *'''[[Lost civilization]]''' | | *'''[[Lost civilization]]''' |
| | + | |
| | ---- | | ---- |
| | | | |
| | | | |
| | *'''[[History of covid19 exploration]]''' | | *'''[[History of covid19 exploration]]''' |
| − |
| |
| − |
| |
| | *'''[[misc.]]''' | | *'''[[misc.]]''' |
| − | {{tp|p=32203708|t=ä. COVID-19 outbreak: less stethoscope, more ultrasound |pdf=|usr=}}
| |
| − | {{tp|p=32192583|t=2020. COVID-19: delay, mitigate, and communicate |pdf=|usr=}}
| |
| − | {{tp|p=32344311|t=2020. 2019-nCoV-SARS-CoV-2 (COVID-19) infection: Cruc?al?ty of Fur?n and relevance w?th cancer |pdf=|usr=}}
| |
| − | {{tp|p=32360951|t=2020. The first Ramadan during COVID-19 pandemic: 1 8 billion Muslims should fast or not?|pdf=|usr=}}
| |
| − | {{tp|p=32368884|t=2020. Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain |pdf=|usr=}}
| |
| | | | |
| | | | |
| | *'''[[Research tools]]''' | | *'''[[Research tools]]''' |
| − | {{tp|p=C7118609|t=ä. NetNCSP: Nonoverlapping closed sequential pattern mining |pdf=|usr=}}
| |
| − | {{tp|p=32365567|t=2020. Lab-on-a-Chip Technologies for the Single Cell Level: Separation, Analysis, and Diagnostics |pdf=|usr=}}
| |
| | | | |
| | + | |
| | + | |
| | + | |
| | + | {{tp|p=27490990|t=2017. AVCpred: an integrated web server for prediction and design of antiviral compounds |pdf=|usr=}} |
| | + | {{tp|p=25040500|t=2014. Engineering large viral DNA genomes using the CRISPR?Cas9 system |pdf=|usr=}} |
| | + | |
| | + | |
| | + | *'''[[PrePrint scene]]''' |
| | | | |
| | | | |
| | *'''[[from the ads]]''' | | *'''[[from the ads]]''' |
| − | *[lifechemicals.com antiviral candidate drugs]
| |
| − | *[biomol.com assays cytokines general spectrum]
| |
| − | *[labospace.com custom single probe assay 400 possible cytokines and so on]
| |
| − | *[codexdna.com dna synthesis]
| |
| − | *[eclipsebio.com around rna]
| |
| | | | |
| | *'''[[Current state of coviki.org]]''' | | *'''[[Current state of coviki.org]]''' |
| | + | *'''[[on-topic personal thoughts]]''' |
